MannKind Dirección
Dirección controles de criterios 3/4
El CEO de MannKind es Michael Castagna , nombrado en May 2017, tiene una permanencia de 7.5 años. compensación anual total es $7.07M, compuesta por 9.9% salario y 90.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.83% de las acciones de la empresa, por valor de $15.60M. La antigüedad media del equipo directivo y de la junta directiva es de 7.3 años y 4.8 años, respectivamente.
Información clave
Michael Castagna
Chief Executive Officer (CEO)
US$7.1m
Compensación total
| Porcentaje del salario del CEO | 9.9% |
| Permanencia del CEO | 7.5yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 7.3yrs |
| Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Compensación vs. Mercado: La compensación total de Michael($USD7.07M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.34M).
Compensación vs. Ingresos: La compensación de Michael ha sido consistente con los resultados de la empresa en el último año.
CEO
Michael Castagna (47 yo)
7.5yrs
Permanencia
US$7,068,114
Compensación
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Chief Operating Officer | 1.7yrs | US$2.74m | 0.025% $ 478.2k | |
| Executive VP | 22.8yrs | US$2.34m | 0.17% $ 3.1m | |
| Executive VP and Chief People & Workplace Officer | 7.9yrs | US$2.22m | 0.22% $ 4.1m | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Executive Vice President of Technical Operations | 2.1yrs | US$1.12m | 0.035% $ 650.2k | |
| VP of Investor Relations & Treasury | 7.3yrs | US$519.59k | sin datos | |
| Senior Vice President of Worldwide Regulatory Affairs | 19.1yrs | sin datos | sin datos | |
| Chief Commercial Officer | 7.3yrs | US$921.51k | sin datos | |
| Executive VP of Research & Development and Chief Medical Officer | 1.5yrs | sin datos | 0.070% $ 1.3m |
7.3yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MNKD es experimentado (7.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$7.07m | 0.83% $ 15.6m | |
| Independent Director | 21.1yrs | US$241.73k | 0.043% $ 805.2k | |
| Chairman Emeritus | less than a year | US$240.64k | 0.096% $ 1.8m | |
| Independent Director | 6yrs | US$226.73k | 0.010% $ 188.3k | |
| Independent Director | 20.9yrs | US$229.23k | 0.0054% $ 101.6k | |
| Independent Director | 4.8yrs | US$233.14k | 0.064% $ 1.2m | |
| Independent Chairman | 9.5yrs | US$255.64k | 0.0089% $ 166.3k | |
| Independent Director | 3.9yrs | US$221.73k | 0.039% $ 727.8k | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Director | less than a year | US$2.34m | 0.20% $ 3.7m | |
| Independent Director | 4.7yrs | US$221.73k | 0.040% $ 752.7k | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos |
4.8yrs
Permanencia media
64.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MNKD se considera experimentada (4.8 años de antigüedad promedio).